Overview

Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment

Status:
Completed

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to determine if the investigational drug is able to reduce/shrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

Capecitabine
Taxane